Physician

Wassim Shaheen, M.D.

According to 2025 Medicare claims, Wassim Shaheen, M.D. (NPI: 1780625558) practices interventional cardiology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is HEARTLAND CARDIOLOGY, LLC (NPI: 1134503840; TIN: 47-4428708) and primary practice location at 67226-8127.

Shaheen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 5,494 traditional Medicare patients, billed 33,014 HCPCS/CPT codes, and received $3,324,174 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 35,336 prescription claims across 4,098 beneficiaries totaling $6,530,750 in drug costs, led by Eliquis (Apixaban). 2020 DME data shows 113 claims. Open Payments data shows 185 records totaling $15,623. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,532,139 to $3,324,174. Similarly, Part D prescription costs have moved sharply higher in recent years, from $594,858 to $6,530,750. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $76,658 to $17,866.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	4,462	35,348	$1,532,139
2016	4,431	34,832	$1,604,118
2017	5,143	39,756	$2,131,322
2018	4,973	34,218	$2,039,365
2019	5,406	32,740	$2,339,307
2020	4,841	29,651	$2,200,522
2021	4,798	32,136	$2,630,085
2022	4,679	30,813	$2,601,338
2023	5,753	34,612	$2,792,362
2024	5,494	33,014	$3,324,174

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,440	14,922	$594,858
2016	1,638	16,548	$825,039
2017	1,834	18,588	$1,100,138
2018	2,106	20,783	$1,458,592
2019	2,400	23,001	$2,003,966
2020	2,732	25,906	$2,874,345
2021	3,070	29,295	$3,786,247
2022	3,243	30,675	$4,574,625
2023	3,703	32,151	$5,574,194
2024	4,098	35,336	$6,530,750

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	424	$358,703
2016	N/R	254	$218,235
2017	N/R	311	$27,092
2018	N/R	124	$12,295
2019	N/R	220	$22,222
2020	N/R	113	$13,187
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	2,615	2,726	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	2,029	2,610	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	3,719	4,721	$56
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	995	1,004	$47
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	3,832	4,224	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	3,943	191,542	$3,718,405
Xarelto	Rivaroxaban	933	52,234	$963,580
Entresto	Sacubitril/Valsartan	713	31,196	$678,863
Farxiga	Dapagliflozin Propanediol	272	11,578	$219,155
Camzyos	Mavacamten	24	720	$203,830

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	184	$3,116	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$12,507	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wassim Shaheen, M.D.?

Tedicare shows public-source Medicare data for Wassim Shaheen, M.D. (NPI 1780625558), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wassim Shaheen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Wassim Shaheen, M.D.?

Wassim Shaheen, M.D. is linked to HEARTLAND CARDIOLOGY, LLC (billing NPI 1134503840) in the available physician profile data.

Does Wassim Shaheen, M.D. have Open Payments data?

Wassim Shaheen, M.D. has 185 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.